ACBAurora Cannabis Inc.
The schedule
- Tue15Sep
Through late 2026, investors will watch for concrete steps on US federal cannabis rescheduling and Canadian regulatory tweaks that could reshape addressable markets and capital access for Aurora Cannabis, with the stock modeled here around $2.9 after Q2 FY26.
- Wed4Nov
- Sun15Nov
Into late 2026, Aurora Cannabis faces an ongoing risk that management may tap equity or convertible markets to extend its cash runway and fund strategic initiatives, with the stock here anchored at $3.0 after Q3 FY26.
- Wed10Mar
By early 2027, Aurora Cannabis may pursue further strategic actions—such as asset rationalizations, partnerships, or M&A—to strengthen its position in a consolidating cannabis market, with the stock here anchored at $2.0 following FY26 results.
- Wed5May
- Wed4Aug
Past
- Wed5Aug
Actual outcome: Bull · $3.82 at outcome
Aurora Cannabis beat earnings estimates with an EPS of $0.0321 versus the estimate of $0.0321, signaling stability in financial performance. The stock surged due to the announcement of a hostile takeover bid by Curaleaf, which valued Aurora shares at a 45% premium, highlighting strong investor interest and potential strategic value, driving the rally despite the neutral earnings report.